Literature DB >> 21572764

Telavancin (vibativ), a new option for the treatment of gram-positive infections.

Polina Plotkin, Khusbu Patel, Amy Uminski, Nino Marzella.   

Abstract

Year:  2011        PMID： 21572764      PMCID： PMC3086107     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  16 in total

1.  Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects.

Authors:  Steven Barriere; Fredric Genter; Elizabeth Spencer; Michael Kitt; David Hoelscher; Joel Morganroth
Journal:  J Clin Pharmacol       Date:  2004-07       Impact factor: 3.126

2.  Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.

Authors:  Shekman L Wong; Fritz Sörgel; Martina Kinzig; Michael R Goldberg; Michael M Kitt; Steven L Barriere
Journal:  J Clin Pharmacol       Date:  2009-05-14       Impact factor: 3.126

4.  Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.

Authors:  Thomas P Lodise; Mark Gotfried; Steven Barriere; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

Review 5.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

6.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Authors:  Martin E Stryjewski; William D O'Riordan; William K Lau; Francis D Pien; Lala M Dunbar; Marc Vallee; Vance G Fowler; Vivian H Chu; Elizabeth Spencer; Steven L Barriere; Michael M Kitt; Christopher H Cabell; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2005-04-28       Impact factor: 9.079

7.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Authors:  Mark H Gotfried; Jeng-Pyng Shaw; Bret M Benton; Kevin M Krause; Michael R Goldberg; Michael M Kitt; Steven L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

9.  Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.

Authors:  Martin E Stryjewski; Vivian H Chu; William D O'Riordan; Brian L Warren; Lala M Dunbar; David M Young; Marc Vallée; Vance G Fowler; Joel Morganroth; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079
View more
  7 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

2.  Quantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS.

Authors:  Xiaoming Wang; Jonathan A Paul; Tatiana N Nanovskaya; Gary D V Hankins; Mahmoud S Ahmed
Journal:  J Pharm Biomed Anal       Date:  2014-05-02       Impact factor: 3.935

3.  Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.

Authors:  Truc T Tran; Vincent H Tam; Barbara E Murray; Cesar A Arias; Kavindra V Singh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Ochsner J       Date:  2013

Review 5.  Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.

Authors:  Martyn Gostelow; Daniel Gonzalez; P Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2014-04-09       Impact factor: 4.108

Review 6.  Update on the emerging role of telavancin in hospital-acquired infections.

Authors:  Obinna N Nnedu; George A Pankey
Journal:  Ther Clin Risk Manag       Date:  2015-04-13       Impact factor: 2.423

Review 7.  Cyclic peptide drugs approved in the last two decades (2001-2021).

Authors:  Huiya Zhang; Shiyu Chen
Journal:  RSC Chem Biol       Date:  2021-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.